N-Acetyl Selank Amidate: Published Research

Introduction

The peer-reviewed literature addressing Selank and its terminally modified variants spans more than two decades of sustained work from the Institute of Molecular Genetics of the Russian Academy of Sciences and collaborating pharmacology institutes. The published corpus covers GABAergic receptor pharmacology, enkephalin-degrading enzyme inhibition, hippocampal neurotrophic signaling, splenic immune gene expression, and behavioral pharmacology across multiple rodent models — a breadth of mechanistic investigation that places Selank among the more comprehensively characterized neuropeptide research compounds of its size class. A comparable depth of institutional research output characterizes Semax, a related Russian neuropeptide with documented melanocortin and BDNF pharmacology, developed at the same Institute of Molecular Genetics research program. N-Acetyl Selank Amidate shares the seven-residue pharmacophore of the parent compound; the terminal modifications that define the variant are expected to extend plasma stability without altering the core receptor pharmacology that the parent-compound literature characterizes. This bibliographic summary organizes key published studies by methodology, with attribution to named sources and explicit notation of the experimental models used.

Methodology Types Represented in the Literature

The Selank research corpus spans several experimental approaches:

• In vitro receptor binding assays: Studies measuring direct interaction between Selank and GABA-A receptor preparations, or competitive displacement of radioligands from receptor binding sites.
• Cell culture gene expression studies: qPCR-based analysis of transcriptional changes in neuronal cell lines (particularly IMR-32 human neuroblastoma cells) following Selank exposure.
• Rodent behavioral models: Elevated-plus-maze, open-field test, and conditioned avoidance paradigms in inbred and outbred rat and mouse lines.
• Rodent withdrawal models: Naloxone-precipitated opioid withdrawal and ethanol withdrawal protocols in rodents.
• In vivo neurochemistry: Measurement of neurotransmitter metabolites, cytokine concentrations, and mRNA/protein levels in dissected rodent brain regions and peripheral tissue following Selank administration.
• Enzymatic assay: Direct measurement of enkephalin-degrading enzyme activity in the presence of Selank.

The parent compound Selank was the subject of clinical investigation in Russia, with a registration granted for the nasal drop formulation [1], documenting an institutional trajectory from basic research through regulatory milestone. Peer-reviewed data from those clinical investigations are represented primarily in the Russian-language literature; the indexed English-language record is dominated by the mechanistic, molecular, and behavioral studies summarized below.

Summary of Studies

GABAergic Receptor Pharmacology

Filatova et al. (2016) — In vivo GABAergic gene expression in rat frontal cortex [2] Filatova and colleagues conducted in vivo experiments in adult rats, measuring the expression of genes involved in GABAergic neurotransmission in the frontal cortex following Selank administration. Using quantitative PCR on tissue samples collected at one hour and three hours post-injection, the study reported that 45 of the 84 genes assessed showed significant expression changes at one hour and 22 genes at three hours. The time-dependent profile of gene expression changes was interpreted as evidence that Selank perturbed GABAergic transcriptional programs in a manner consistent with receptor-level allosteric modulation. Published in Frontiers in Pharmacology, available through PubMed Central (PMC4757669).

Findings from research models do not establish safety or efficacy in humans. SpartaLabs makes no claims about the use of this compound.

Volkova et al. (2017) — GABAergic gene expression in IMR-32 human neuroblastoma cells [3] This study from the same research group examined the effect of Selank, exogenous GABA, and olanzapine — individually and in combinations — on 84 GABAergic genes in IMR-32 cells. In combination with GABA, Selank was reported to produce near-complete suppression of the expression changes that GABA alone induced, and in combination with olanzapine, expression alterations were observed in additional genes relative to olanzapine alone. These combinatorial findings characterize Selank as a context-dependent modulator of GABAergic gene programs — a pharmacological feature of research interest given the mechanistic contrast with direct GABA agonists. Published in Frontiers in Pharmacology (PMC5328971).

Kolik et al. (2018) — Comparative intranasal and intraperitoneal pharmacology in two mouse strains [4] This study compared behavioral and receptor-level effects of Selank in BALB/c mice (high-anxiety phenotype) and C57BL/6 mice (lower-anxiety phenotype). In BALB/c mice, intraperitoneal Selank was associated with a 38% increase in GABA-A receptor binding sites in the frontal cortex using [³H]SR 95531 radioligand. Neither the behavioral nor receptor-level effects were consistently replicated in C57BL/6 mice. The authors noted that baseline anxiety phenotype modulated the pharmacological response — a finding relevant to research design when selecting animal models for GABAergic compound investigation. Published in Eksperimentalnaya i Klinicheskaya Farmakologiya (PMID: 29787664).

Zozulya et al. (2018) — Mechanistic review of Selank biological activity [5] This peer-reviewed article in Protein and Peptide Letters provided a comprehensive synthesis of the molecular mechanisms reported for Selank across multiple prior studies. The authors characterized Selank as exhibiting subtype-selective, concentration-dependent allosteric modulation of GABA-A receptors, with the capacity to block the modulatory actions of both diazepam and olanzapine on [³H]GABA binding — a mechanistic profile they described as distinct from classical benzodiazepines despite partial GABAergic overlap. The review also integrated the enkephalin-degrading enzyme inhibition data, providing the most comprehensive single-source treatment of Selank's mechanistic pharmacology available in the English-language indexed literature (PMID: 30255741).

Enkephalin System Studies

Semenova et al. (2001) — Enkephalin-degrading enzyme inhibition [6] This foundational study from the Institute of Molecular Genetics reported that Selank dose-dependently inhibited the enzymatic hydrolysis of plasma enkephalin in vitro, with an IC₅₀ of approximately 15 micromolar — a potency greater than that of reference enkephalinase inhibitors bacitracin and puromycin in the same assay. The study also reported that patients with generalized anxiety disorders exhibited reduced total enkephalinase activity in blood samples relative to healthy controls, establishing a biological rationale for enkephalin stabilization as a pharmacological approach and providing the conceptual framework for much of the subsequent Selank behavioral research (PMID: 11550013).

Kolik et al. (2012) — Opioid system involvement in Selank's behavioral effects [7] To examine whether opioid receptor signaling contributed to Selank's behavioral effects, this study pre-treated BALB/c and C57BL/6 mice with naloxone before Selank administration. In BALB/c mice, naloxone pretreatment attenuated the behavioral response to Selank. The authors interpreted the naloxone-sensitive component as indicating that the endogenous enkephalin-opioid system partially mediates Selank's behavioral pharmacology — a finding that mechanistically connected the in vitro enkephalinase inhibition data to an in vivo behavioral outcome and informed the design of subsequent withdrawal model studies (PMID: 22550852).

Konstantinopolsky et al. (2022) — Morphine withdrawal in rats [8] This study from the V. V. Zakusov Research Institute of Pharmacology investigated Selank's effects in an opioid withdrawal model. Outbred rats receiving repeated morphine administration underwent naloxone-precipitated withdrawal, and Selank administration was associated with a 39.6% reduction in the composite withdrawal index, with significant attenuation of convulsive reactions, ptosis, and posture disorders. The authors attributed these effects to the peptide's reported actions on the enkephalin-opioid system, extending over two decades of enkephalinase inhibition research into a model directly relevant to opioid pharmacology. Published in the Bulletin of Experimental Biology and Medicine (PMID: 36322304).

Neurotrophin and Hippocampal Studies

Kolomin et al. (2008) — BDNF expression in rat hippocampus [9] This study examined whether intranasal Selank administration altered BDNF expression in rat hippocampal tissue. Bdnf mRNA was reported to be elevated at three hours after administration relative to controls, and BDNF protein was reported to be elevated at 24 hours. The regional analysis indicated that the BDNF changes reflected local transcriptional activation in hippocampal neurons. The finding extended the mechanistic picture of Selank's CNS pharmacology beyond receptor binding and gene expression in the frontal cortex to include neurotrophic signaling in hippocampal tissue. Published in Doklady Biological Sciences (PMID: 18841804).

Gene Expression in Peripheral Tissue

Kolomin et al. (2011) — Inflammation-related genes in mouse spleen [10] This study analyzed the expression of 84 genes involved in inflammation — including chemokines, cytokines, and their receptors — in mouse spleen tissue at six and 24 hours following a single intraperitoneal injection of Selank. Differential gene expression at both time points was reported, with the pattern suggesting modulation of splenic immune signaling consistent with the tuftsin structural lineage of the compound. Published in Regulatory Peptides (PMID: 21609736), the study extended Selank's documented pharmacological reach from CNS pharmacology into peripheral immune tissue gene regulation.

Cytokine Modulation Under Stress

Kolik et al. (2020) — Cytokines during social stress [11] This rodent study examined cytokine levels under conditions of experimental social stress. Animals receiving Selank were reported to show concentrations of IL-1β, IL-6, TNF-α, and TGF-β1 closer to unstressed control values than those observed in stressed, untreated animals. The authors characterized the findings as evidence of stress-protective activity operating through immunological pathways, consistent with the tuftsin structural origin of Selank and with the splenic gene expression data reported by Kolomin et al. (2011) (PMID: 32621722).

Alcohol Withdrawal

Kolik et al. (2014) — Alcohol withdrawal syndrome in rats [12] This study used a rat model in which animals were given access to 10% ethanol for 24 weeks to establish stable alcoholic motivation, then underwent 48-hour withdrawal. A single Selank administration was associated with attenuation of anxiety-like behavior and mechanical allodynia during the withdrawal period, without a corresponding change in voluntary ethanol consumption in subsequent measurement. The investigators noted the selectivity of the effect — withdrawal-state attenuation without alteration of ongoing consumption — as consistent with the compound's mechanistic profile in enkephalin-opioid system pharmacology. Published in Eksperimentalnaya i Klinicheskaya Farmakologiya (PMID: 24913576).

Active Research Frontier

The Selank research program has progressed across methodological generations — from behavioral observation, through enzymatic and receptor-binding assay, to molecular gene expression profiling — with each generation adding mechanistic resolution to the GABAergic/enkephalinergic pharmacological framework established in the early 2000s. The most recent indexed publications (2020–2022) extended the opioid-withdrawal and stress-cytokine lines of investigation, indicating active productivity in the research program. Researchers procuring material for studies referencing this corpus may review batch purity specifications on the N-Acetyl Selank Amidate product page.

For N-Acetyl Selank Amidate specifically, characterization studies examining how the dual terminal modification affects receptor affinity, plasma pharmacokinetics, and behavioral potency relative to the parent compound represent the next logical step for the research community. The terminal modification strategy is well-precedented across the broader peptide chemistry literature, and the mechanistic rationale for expecting preserved or amplified pharmacophore activity is established; direct experimental confirmation in published primary research remains an area of ongoing investigation. For an account of the institutional and regulatory history underlying this research program, see N-Acetyl Selank Amidate: Discovery and Research History.

For overview chemistry and classification, see N-Acetyl Selank Amidate: A Research Overview.

References

1. Deigin VI, Poluektova EA, Beniashvili AG, Kozin SA, Poluektov YM. Development of Peptide Biopharmaceuticals in Russia. Pharmaceutics. 2022;14(4):716. PMID: 35456550. DOI: 10.3390/pharmaceutics14040716. PMC: PMC9030433.

2. Filatova EV, Shadrina MI, Slominsky PA, Boldyrev AA, Lyapina LA, Andreeva LA, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016;6:317. PMID: 26793110. DOI: 10.3389/fphar.2015.00317. PMC: PMC4757669.

3. Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, et al. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Front Pharmacol. 2017;8:89. PMID: 28293190. DOI: 10.3389/fphar.2017.00089. PMC: PMC5328971.

4. Kolik LG, Nadorova AV, Konstantinopolsky MA. Comparison of Pharmacological Effects of Heptapeptide Selank After Intranasal and Intraperitoneal Administration to BALB/c and C57BL/6 Mice. Eksperimentalnaya i Klinicheskaya Farmakologiya. 2018;81(3):3-8. PMID: 29787664.

5. Zozulya AA, Neznamov GG, Siuniakov TS, Kost NV, Gar'kavaia ER, Siuniakov SA, et al. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett. 2018;25(10):914-923. PMID: 30255741. DOI: 10.2174/0929866525666180925143003.

6. Semenova TP, Kozlovskaya MM, Zuikov AV, Kozlovskiy II, Zuikov PV, Lygalov AV. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Eksperimentalnaya i Klinicheskaya Farmakologiya. 2001;64(4):15-7. PMID: 11550013.

7. Kolik LG, Konstantinopolsky MA, Seredenin SB. The role of opioid system in peculiarities of anti-anxiety effect of peptide anxiolytic selank. Eksperimentalnaya i Klinicheskaya Farmakologiya. 2012;75(4):3-6. PMID: 22550852.

8. Konstantinopolsky MA, Chernyakova IV, Kolik LG. Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. Bull Exp Biol Med. 2022;173(6):722-726. PMID: 36322304. DOI: 10.1007/s10517-022-05624-x.

9. Kolomin T, Shadrina M, Agniullin Y, Shram S, Slominskii P, Limborska S, et al. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008;421:241-3. PMID: 18841804. DOI: 10.1134/S0012496608040066.

10. Kolomin T, Shadrina M, Slominsky P, Limborska S, Myasoedov N. Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank. Regul Pept. 2011;170(1-3):18-23. PMID: 21609736. DOI: 10.1016/j.regpep.2011.05.001.

11. Kolik LG, Nadorova AV, Konstantinopolsky MA. The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress. Eksperimentalnaya i Klinicheskaya Farmakologiya. 2020;83(6):3-7. PMID: 32621722.

12. Kolik LG, Nadorova AV, Konstantinopolsky MA. Efficacy of peptide anxiolytic selank during modeling of withdrawal syndrome in rats with stable alcoholic motivation. Eksperimentalnaya i Klinicheskaya Farmakologiya. 2014;77(4):7-10. PMID: 24913576.